Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/10/2018
SIETES contiene 92571 citas

 
 
 1 a 20 de 296 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Zash R, Makhema J, Shapiro RL. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med 2018:24 de julio. [Ref.ID 102748]
2.Tiene citas relacionadas Cita con resumen
Rasmussen SA, Barfield W, Honein MA. Protecting mothers and babies — A delicate balancing act. N Engl J Med 2018:24 de julio. [Ref.ID 102747]
3. Cita con resumen
Anónimo. Valproato (Depakine / Depakine Crono): programa de prevención de embarazos. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:24 de julio. [Ref.ID 102721]
4. Cita con resumen
Hirschler B. Regulators flag possible birth defect link to GSK's HIV drug. Reuters Health News 2018:18 de mayo. [Ref.ID 102606]
5.Enlace a cita original Cita con resumen
Bergman JEH, Lutke LR, Gans ROB, Addor M-C, Barisic I, Clavero-Carbonell C, Garne E, Gatt M, Klungsoyr K, Lelong N, Lynch C, Mokoroa O, Nelen V, Neville AJ, Pierini A, Randrianaivo H, Rißmann A, Tucker D, Wiesel A, Dolk H, Loane M, Bakker MK. Beta-blocker use in pregnancy and risk of specific congenital anomalies: A European case-malformed control study. Drug Saf 2018;41:415-27. [Ref.ID 102566]
6. Cita con resumen
Pennel PB. Prescribing antiepileptic drugs to women of reproductive age. Lancet Neurol 2018;17:485-6. [Ref.ID 102517]
7. Cita con resumen
Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, Sabers A, Thomas SV, Vajda F, for the EURAP study group. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018;17:530-8. [Ref.ID 102516]
8. Cita con resumen
Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]
9. Cita con resumen
Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, Neovius M. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ 2017;357:j2563. [Ref.ID 101639]
10. Cita con resumen
Casassus B. Drug scandals in France: have the lessons been learnt?. Lancet 2016;388:550-2. [Ref.ID 100574]
11.Enlace a cita original
Bérard A, Sheehy O, Zhao J-P, Nordeng H. Use of macrolides during pregnancy and rik of birth defects: a population-based study. Pharmacoepidemiol Drug Saf 2015;24:1241-8. [Ref.ID 99787]
13.Tiene citas relacionadas Cita con resumen
Clarke R, Bennett D. Folate and prevention of neural tube defects. BMJ 2014;349:g4810. [Ref.ID 98164]
14. Cita con resumen
Pastemak B, Svanström H, Molgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA 2013;310:1601-11. [Ref.ID 96391]
15. Cita con resumen
Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosenbraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012;367:1577-9. [Ref.ID 93939]
16.Enlace a cita original Cita con resumen
Anónimo. Change in the pregnancy category for topiramate. Australian Prescriber 2012;35:66. [Ref.ID 93159]
17.Tiene citas relacionadas Cita con resumen
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strenghts of the disproportionality analysis of identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905-8. [Ref.ID 91873]
19.Tiene citas relacionadas Cita con resumen
Mitchell AA. Fetal risk from ACE inhibitors in the first trimester. BMJ 2011;343:857-8. [Ref.ID 91753]
20. Cita con resumen
Roth C, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Folic acid supplements in pregnancy and severe language delay in children. JAMA 2011;306:1566-73. [Ref.ID 91544]
Seleccionar todas
 
 1 a 20 de 296 siguiente >>